These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 16844315)

  • 1. Statins may decrease skeletal-related events in breast cancer patients with bone metastases.
    Dincer M; Bulut N; Harputluoglu H; Altundag K
    Med Hypotheses; 2006; 67(5):1146-7. PubMed ID: 16844315
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacotherapy of bone metastases in breast cancer patients.
    Petrut B; Simmons C; Broom R; Trinkaus M; Clemons M
    Expert Opin Pharmacother; 2008 Apr; 9(6):937-45. PubMed ID: 18377337
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [The application advances of bisphosphonates in bone metastasis].
    Liang P
    Zhongguo Gu Shang; 2008 Jun; 21(6):480-2. PubMed ID: 19108448
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mechanisms of osteolytic bone metastases in breast carcinoma.
    Käkönen SM; Mundy GR
    Cancer; 2003 Feb; 97(3 Suppl):834-9. PubMed ID: 12548583
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase II trial evaluating the palliative benefit of second-line zoledronic acid in breast cancer patients with either a skeletal-related event or progressive bone metastases despite first-line bisphosphonate therapy.
    Clemons MJ; Dranitsaris G; Ooi WS; Yogendran G; Sukovic T; Wong BY; Verma S; Pritchard KI; Trudeau M; Cole DE
    J Clin Oncol; 2006 Oct; 24(30):4895-900. PubMed ID: 17001071
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Statins can inhibit proliferation of human breast cancer cells in vitro.
    Seeger H; Wallwiener D; Mueck AO
    Exp Clin Endocrinol Diabetes; 2003 Feb; 111(1):47-8. PubMed ID: 12605351
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Anabolic effects of statin and beta-blocker on bone metabolism].
    Taguchi M; Takeuchi Y
    Clin Calcium; 2004 Dec; 14(12):89-94. PubMed ID: 15577180
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Breast cancer growth prevention by statins.
    Campbell MJ; Esserman LJ; Zhou Y; Shoemaker M; Lobo M; Borman E; Baehner F; Kumar AS; Adduci K; Marx C; Petricoin EF; Liotta LA; Winters M; Benz S; Benz CC
    Cancer Res; 2006 Sep; 66(17):8707-14. PubMed ID: 16951186
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Bisphosphonates in the therapy of cancer patients].
    Jantunen E; Kumpulainen E
    Duodecim; 1999; 115(1):27-32. PubMed ID: 11830857
    [No Abstract]   [Full Text] [Related]  

  • 10. Efficacy and safety of zoledronic acid in patients with breast cancer metastatic to bone: a multicenter clinical trial.
    Cartenì G; Bordonaro R; Giotta F; Lorusso V; Scalone S; Vinaccia V; Rondena R; Amadori D
    Oncologist; 2006; 11(7):841-8. PubMed ID: 16880243
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Statins, fracture risk, and bone remodeling.
    Luisetto G; Camozzi V
    J Endocrinol Invest; 2009; 32(4 Suppl):32-7. PubMed ID: 19724164
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Understanding and optimizing bone health in breast cancer.
    Guise TA; Brufsky A; Coleman RE
    Curr Med Res Opin; 2010 Dec; 26 Suppl 3():3-20. PubMed ID: 21050131
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical features of metastatic bone disease and risk of skeletal morbidity.
    Coleman RE
    Clin Cancer Res; 2006 Oct; 12(20 Pt 2):6243s-6249s. PubMed ID: 17062708
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Statins and breast cancer: may matrix metalloproteinase be the missing link.
    Mannello F; Tonti GA
    Cancer Invest; 2009 May; 27(4):466-70. PubMed ID: 19219650
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A comparison between the effects of hydrophobic and hydrophilic statins on osteoclast function in vitro and ovariectomy-induced bone loss in vivo.
    Hughes A; Rogers MJ; Idris AI; Crockett JC
    Calcif Tissue Int; 2007 Nov; 81(5):403-13. PubMed ID: 17982704
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lowering bone mineral affinity of bisphosphonates as a therapeutic strategy to optimize skeletal tumor growth inhibition in vivo.
    Fournier PG; Daubiné F; Lundy MW; Rogers MJ; Ebetino FH; Clézardin P
    Cancer Res; 2008 Nov; 68(21):8945-53. PubMed ID: 18974139
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Post-diagnosis statin use and breast recurrence sites in early stage breast cancer survivors.
    Harputluoglu H; Dizdar O; Karaahmet F; Altundag K
    Breast Cancer Res Treat; 2008 Aug; 110(3):541. PubMed ID: 17851754
    [No Abstract]   [Full Text] [Related]  

  • 18. A cathepsin K inhibitor reduces breast cancer induced osteolysis and skeletal tumor burden.
    Le Gall C; Bellahcène A; Bonnelye E; Gasser JA; Castronovo V; Green J; Zimmermann J; Clézardin P
    Cancer Res; 2007 Oct; 67(20):9894-902. PubMed ID: 17942921
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of statins in cancer therapy.
    Hindler K; Cleeland CS; Rivera E; Collard CD
    Oncologist; 2006 Mar; 11(3):306-15. PubMed ID: 16549815
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Statins, stem cells, and cancer.
    Gauthaman K; Fong CY; Bongso A
    J Cell Biochem; 2009 Apr; 106(6):975-83. PubMed ID: 19224538
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.